Process Development
Process development plays a critical role in transforming oligonucleotide candidates into manufacturable drug substances by establishing robust, scalable, and reproducible production processes. From synthesis route optimization to CMC development and process characterization, a well-designed development strategy helps improve product quality, manufacturing efficiency, and readiness for clinical and commercial production. Protheragen provides integrated oligonucleotide process development services covering solid-phase synthesis route development, CMC process development, and customized process development for ASOs, siRNAs, PMOs, and CpG oligonucleotides.
Overview of Process Development
Oligonucleotide process development bridges early sequence design with scalable manufacturing by establishing robust, reproducible, and efficient production strategies. It encompasses synthesis route optimization, purification process development, analytical integration, and process characterization to support the transition from research candidates to clinical and commercial manufacturing.
Different classes of oligonucleotide therapeutics, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), phosphorodiamidate morpholino oligomers (PMOs), and CpG oligonucleotides, present unique manufacturing challenges due to differences in sequence length, chemical modification, conjugation strategy, and product quality requirements. Tailored process development approaches help improve manufacturing efficiency while supporting product quality and regulatory expectations.
A comprehensive process development strategy typically integrates solid-phase synthesis optimization, impurity control, purification strategy development, in-process analytical testing, and scalability assessment. Early consideration of manufacturability and critical process parameters can facilitate technology transfer and subsequent GMP manufacturing.
Fig.1 Schematic representation of the ON synthesis with blocks: solid-phase ON synthesis steps and cleavage from the solid support and deprotection. (Abe A, et al., 2025)
Our Services
From early-stage development to manufacturing readiness, oligonucleotide process development requires a comprehensive understanding of synthesis chemistry, purification strategies, analytical requirements, and scalability considerations. Protheragen provides integrated process development solutions tailored to different oligonucleotide modalities, helping clients establish robust and efficient manufacturing processes while supporting smooth progression toward clinical and commercial production.
Solid-phase Synthesis Route Development
Solid-phase synthesis is a fundamental manufacturing approach for oligonucleotide therapeutics. Developing an optimized synthesis route requires careful evaluation of coupling efficiency, chemical modification compatibility, reaction conditions, and impurity generation throughout the synthesis cycle.
Protheragen provides solid-phase synthesis route development services to optimize oligonucleotide production processes, improve synthesis performance, and establish reproducible manufacturing strategies for diverse oligonucleotide candidates.
CMC Process Development
CMC process development establishes the foundation for successful clinical translation and commercial manufacturing of oligonucleotide therapeutics. It integrates process optimization, analytical evaluation, quality assessment, and documentation strategies to ensure product consistency and regulatory readiness.
Protheragen supports comprehensive CMC development programs by integrating chemistry, process science, and analytical expertise to facilitate the transition from discovery candidates to scalable manufacturing processes.
Drug Process Development
Different oligonucleotide therapeutic modalities exhibit distinct chemical structures, mechanisms of action, and manufacturing requirements. Customized drug process development strategies are essential to address modality-specific challenges and optimize production performance.
Protheragen offers tailored process development solutions for various oligonucleotide drug classes, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), phosphorodiamidate morpholino oligomers (PMOs), and CpG oligonucleotides.
Key Process Development Capabilities
Solid-phase Synthesis Optimization
Optimization of solid-phase synthesis conditions to improve coupling efficiency, reduce by-product formation, and support reproducible oligonucleotide production.
Process Characterization
Identification and evaluation of critical process parameters and process performance to establish robust manufacturing strategies.
Purification Development
Development of purification strategies using chromatography and related technologies to improve purity and impurity control.
Scale-up Assessment
Evaluation of process scalability and technology transfer readiness from laboratory development to GMP manufacturing.
CMC Integration
Integrated CMC development supporting process documentation, analytical methods, regulatory readiness, and manufacturing consistency.
Applications of Oligonucleotide Process Development
Oligonucleotide therapeutics have expanded rapidly across multiple therapeutic areas due to their ability to selectively regulate gene expression and target disease-related RNA pathways. Robust process development strategies are essential to support different oligonucleotide modalities, from early research candidates to clinical-stage and commercial products.
Protheragen's process development platform supports a broad range of oligonucleotide applications, enabling customized manufacturing solutions for RNA-targeting therapies, genetic disorders, oncology, infectious diseases, and immune-related indications.
Gene Regulation and Rare Disease Therapeutics
Oligonucleotide therapies provide powerful approaches for regulating disease-associated genes and correcting abnormal RNA processing.
| Applications |
Representative Modalities |
Splicing modulation
mRNA degradation
Gene expression regulation
Mutation-related disorders
|
ASO
siRNA
PMO
|
Cancer-Related Molecular Targets
Oligonucleotide therapeutics are being investigated for cancer treatment by regulating oncogenic pathways, immune responses, and tumor-associated targets.
| Applications |
Representative Modalities |
Gene silencing
Immune modulation
Targeted molecular therapy
|
siRNA
CpG oligonucleotides
Antisense oligonucleotides
|
- Cardiovascular and Metabolic Diseases
RNA-Based Therapeutic Regulation
RNA-targeting approaches provide opportunities for treating metabolic disorders and cardiovascular diseases through selective regulation of disease-related genes.
| Applications |
Representative Modalities |
Lipid metabolism regulation
Protein expression control
Targeted gene silencing
|
siRNA
ASO
|
Targeted Nucleic Acid-Based Therapies
Oligonucleotide technologies offer potential solutions for controlling viral replication and regulating pathogen-associated genes.
| Applications |
Representative Modalities |
Viral RNA targeting
Antiviral gene regulation
Immune pathway modulation
|
ASO
siRNA
CpG
|
- Vaccines and Immunotherapy
Immune Activation and Modulation
CpG oligonucleotides and other nucleic acid-based molecules can stimulate immune responses and support next-generation vaccine and immunotherapy development.
| Applications |
Representative Modalities |
Vaccine adjuvants
Immune pathway activation
Cancer immunotherapy
|
CpG oligonucleotide
|
Why Choose Protheragen
Integrated development from synthesis optimization to manufacturing.
Support for diverse oligonucleotide modalities and chemical modifications.
Process strategies designed for seamless scale-up and technology transfer.
- Quality-focused Development
Integrated analytical support and process characterization throughout development.
Developing a scalable and reliable manufacturing process is essential for advancing oligonucleotide therapeutics from discovery to clinical development and commercial production. Protheragen combines expertise in oligonucleotide chemistry, process optimization, analytical integration, and CMC development to support the development of high-quality oligonucleotide drug candidates. With flexible development strategies tailored to ASOs, siRNAs, PMOs, CpG oligonucleotides, and other emerging nucleic acid therapeutics, we help partners overcome process challenges and establish robust pathways toward successful manufacturing. Contact us to discuss your oligonucleotide development goals, including synthesis optimization, CMC strategy, process characterization, and scale-up planning.
Reference
- Abe A, et al. "Overview and Recent Advances in the Purification and Isolation of Therapeutic Oligonucleotides" Org. Process Res. Dev. 2025; 29 (1): 15–33.
